| Treffer 1 - 4 |  |
| ART-NR | PRODUKT | HERSTELLER | MENGE | PREIS |
| Cay10010265-5 |
CAS: 244240-24-2 Tyrosine kinase inhibitor  LFM-A13 is an anti-leukemia agent with apoptosis-promoting and chemosensitizing properties. It acts as an inhibitor of Bruton · s tyrosine kinase (BTK) and Polo-like kinase (Plk) with IC50 values of 2.5 µM (murine recombinant) and 10 µM (Xenopus), respectively. LFM-A13 exhibits minor inhibitory activity against a number of other protein kinases including JAK1, JAK2, EGFR, IRK, IKK, and CDK1, 2 and 3, as well as several other related kinases. LFM-A13 also exhibits anti-proliferative activity against Her2/Neu-overexpressing breast cancer cells. MW: 360 D Formula: C11H8Br2N2O2 Purity: >98% |
Cayman |
5 mg |
64 €
 |
| Cay10010265-10 |
CAS: 244240-24-2 Tyrosine kinase inhibitor LFM-A13 is an anti-leukemia agent with apoptosis-promoting and chemosensitizing properties. It acts as an inhibitor of Bruton · s tyrosine kinase (BTK) and Polo-like kinase (Plk) with IC50 values of 2.5 µM (murine recombinant) and 10 µM (Xenopus), respectively. LFM-A13 exhibits minor inhibitory activity against a number of other protein kinases including JAK1, JAK2, EGFR, IRK, IKK, and CDK1, 2 and 3, as well as several other related kinases. LFM-A13 also exhibits anti-proliferative activity against Her2/Neu-overexpressing breast cancer cells. MW: 360 D Formula: C11H8Br2N2O2 Purity: >98% |
Cayman |
10 mg |
122 €
|
| Cay10010265-100 |
CAS: 244240-24-2 Tyrosine kinase inhibitor LFM-A13 is an anti-leukemia agent with apoptosis-promoting and chemosensitizing properties. It acts as an inhibitor of Bruton · s tyrosine kinase (BTK) and Polo-like kinase (Plk) with IC50 values of 2.5 µM (murine recombinant) and 10 µM (Xenopus), respectively. LFM-A13 exhibits minor inhibitory activity against a number of other protein kinases including JAK1, JAK2, EGFR, IRK, IKK, and CDK1, 2 and 3, as well as several other related kinases. LFM-A13 also exhibits anti-proliferative activity against Her2/Neu-overexpressing breast cancer cells. MW: 360 D Formula: C11H8Br2N2O2 Purity: >98% |
Cayman |
100 mg |
893 €
|
| Cay10010265-50 |
CAS: 244240-24-2 Tyrosine kinase inhibitor LFM-A13 is an anti-leukemia agent with apoptosis-promoting and chemosensitizing properties. It acts as an inhibitor of Bruton · s tyrosine kinase (BTK) and Polo-like kinase (Plk) with IC50 values of 2.5 µM (murine recombinant) and 10 µM (Xenopus), respectively. LFM-A13 exhibits minor inhibitory activity against a number of other protein kinases including JAK1, JAK2, EGFR, IRK, IKK, and CDK1, 2 and 3, as well as several other related kinases. LFM-A13 also exhibits anti-proliferative activity against Her2/Neu-overexpressing breast cancer cells. MW: 360 D Formula: C11H8Br2N2O2 Purity: >98% |
Cayman |
50 mg |
510 €
|
|
|
Datenbank vom 14.06.2013, 14:39 Uhr Die Preise verstehen sich exkl. Versandkosten, eventuell anfallender Kühlmittelpauschale sowie der jeweils geltenden Mehrwertsteuer |
1 |
|
Warenkorb
